trending Market Intelligence /marketintelligence/en/news-insights/trending/wrzf0qjjrykyehl47ehasw2 content esgSubNav
In This List

Pfenex nets $39.4M in common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pfenex nets $39.4M in common stock offering

Pfenex Inc. closed a public offering of common stock to raise about $39.4 million in net proceeds.

The San Diego-based biotechnology company issued 7.82 million common shares at $5.50 apiece to raise the funds, which will be used for obtaining regulatory approval and commercializing its osteoporosis medicine PF708.

Barclays Capital Inc. and William Blair & Co. LLC acted as joint book-running managers for the offering.